By Sabela Ojea
Renovaro said it named Nathen Fuentes as its permanent finance chief to succeed interim CFO Simon Tarsh.
The cancer diagnostics and therapeutics company on Tuesday said Fuentes, who previously served as CFO of Telomir Pharmaceuticals, has experience leading acquisition and organic growth initiatives.
The Los Angeles-based company on Monday agreed to acquire Predictive Oncology, which owns a database of 150,000 frozen and live tumor samples and more than 20 years of drug-response data.
In a letter to shareholders, Chief Executive David Weinstein also said Nasdaq notified the company it is now in good standing.
He added that the company has now "taken critical steps in building a point of care cancer detection and vaccine company and will continue to update you regularly on our progress."
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
January 07, 2025 09:49 ET (14:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.